Published in Gene Therapy Weekly, February 10th, 2000
Vascular endothelial growth factor (VEGF) is a potent mediator of solid tumor growth.
At the 7th Meeting of the European Society of Gene Therapy, held November 26-28, 1999, in Munich, Germany, Mi-Ae Kang and colleagues presented their study in which they blocked VEGF to induce tumor regression. Their study is titled "The growth inhibition of hepatoma cells by gene transfer of antisense vascular endothelial growth factor."
In this attempt to block VEGF, the recombinant mammalian expressing vector bearing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2000-02-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.